22 results about "Neurite growth" patented technology

The invention discloses a ketamine derivative and application thereof in treatment of mental diseases, and belongs to the technical field of medicines. The compound or the pharmaceutical composition thereof provided by the invention can obviously improve the expression quantity of nerve cells BDNF, promote the growth of neurite, inhibit NMDA receptor signals and treat acute and chronic depression, has improved oral bioavailability compared with ketamine, and can be used for treating mental diseases such as depression.

A neurite growth stimulant is a small molecule ENPP1 inhibitor. Small molecule ENPP1 inhibitors are capable of treating central nervous system (CNS) injury and promoting axonal regeneration. The ENPP1 inhibitor in the carrier can be administered at damaged nerves and their cell bodies to promote the regeneration of axons.

The present invention addresses the problem of providing a novel technique for promoting neurite outgrowth activity. The present invention for solving the aforementioned e problem is a glial-cell-dependent neurite outgrowth promoter comprising an NF-κB decoy as an active ingredient, the glial-cell-dependent neurite outgrowth promoter being used in order to promote neurite outgrowth of nerve cells via glial cells.

A method for performing an in vitro assay of a biological material may include freezing a biological material sample and slicing the frozen biological material sample into at least one biological material slice. The at least one biomaterial slice may have a thickness of about 10 [mu] m to about 50 [mu] m. The method may further include placing the at least one section of biological material onto a slide; attaching neurons or a population of neurons to an end portion of the at least one slice of biological material to produce a test construct; incubating the test construct; and determining an amount of neurite growth from the neurons or the population of neurons along the at least one slice of biological material.

Compositions of Allopregnanolone (Allo), and methods of use thereof for treating and preventing Alzheimer's Disease (AD) or dementia have been developed. In some embodiments, the amount of Allo effective to treat AD or dementia is between about 2 mg and about 10 mg, preferably 4 mg per dose. Methods for identifying subjects for treatment of AD or dementia are also provided. The methods include selecting a subject having one or more Apo E4 gene alleles. Methods of treating a human subject having AD or at risk of AD OR DEMENTIA are provided. The methods include administering a dosage of from 2 mg to 6 mg to the subject once within a 24 hour period. The dosing is repeated every seven days, or less frequently. The methods stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes.

The present application relates to the technical field of biological medicine, and particularly relates to a composition for protecting cochlear spiral ganglion neurons and application thereof. The composition comprises Panax notoginseng saponins (PNS) and Polygonatum sibiricum polysaccharide (PSP). Research shows that the composition can significantly improve the survival rate of neurons, promote neurite growth, reduce the level of reactive oxygen species, inhibit cell apoptosis, and promote autophagy by regulating the PI3K / AKT signaling pathway, thereby effectively resisting ototoxicity damage induced by aminoglycoside antibiotics. The present application further provides the use of the composition in the preparation of a drug for preventing or treating sensorineural hearing loss.

The invention relates to a short peptide. The short peptide is composed of an amino acid sequence with at least 85% sequence similarity with a sequence number: 1. In accordance with certain embodiments of the present disclosure, the oligopeptides consist of amino acid sequences having 100% sequence similarity to sequence numbers: 1, 2, 3 or 4. In accordance with certain embodiments of the present disclosure, the oligopeptides can treat neurological diseases by enhancing neurite growth. Therefore, the present disclosure also relates to a pharmaceutical composition comprising the oligopeptide and its use in the treatment of neurological diseases.

The present disclosure provides polypeptides that are capable of specifically binding to a FAM19A5 protein, and thereby, inhibit the interaction between members of the LRRC4 protein family and the FAM19A5 protein. In some aspects, the polypeptide comprises a FAM19A5 binding domain of the LRRC4 protein family members. The present disclosure also provides methods for promoting neurite outgrowth by administering a polypeptide described herein.

The invention relates to an application of 9-Methylfacaplysin in preparation of a medicine for treating or preventing nervous system diseases. The medicine comprises one of a tablet containing 9-Methylfacaplysin, a capsule containing 9-Methylfacaplysin, a pill containing 9-Methylfacaplysin, an injection containing 9-Methylfacaplysin, an oral preparation containing 9-Methylfacaplysin and a suspension containing 9-Methylfacaplysin. The nervous system diseases comprise at least one of the following diseases: Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, ischemic cerebral apoplexy, hemorrhagic cerebral apoplexy and traumatic brain injury. The 9-Methylfacaplysin can play a role in promoting the growth and regeneration of neurite, and can be used for treating neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis and the like, and various nervous system diseases such as ischemic cerebral apoplexy, hemorrhagic cerebral apoplexy, traumatic brain injury and the like.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients. In another aspect, tryptamine compositions described herein enhance neuroplasticity by promoting neuronal branching through the formation of neurites (i.e., neurite outgrowth) and neurite elongation (i.e., increasing neurite length).

To provide novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto; and to provide polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies.SOLUTION: Provided is a human-derived recombinant monoclonal anti-Nogo-A antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof binding to the Nogo-A-Δ20 domain and being capable of inducing dose-dependent neurite outgrowth and / or angiogenesis in stroke penumbra.SELECTED DRAWING: None

This specification discloses short-chain peptides having an amino acid sequence at least 85% identical to SEQ ID NO: 1. According to some embodiments of this disclosure, these short-chain peptides have an amino acid sequence 100% identical to SEQ ID NO: 1, 2, 3, or 4. According to certain embodiments of this disclosure, these short-chain peptides are useful for treating neurological disorders by enhancing neurite outgrowth. Accordingly, this specification also discloses pharmaceutical compositions containing these short-chain peptides and their use for treating neurological disorders.

To obtain an anti-RepulsiveGuidanceMoleculea (RGMa) antibody which can be used as a medicine for preventing, treating or preventing the recurrence of neurological diseases or immunological diseases, has high binding activity and little side effects.SOLUTION: The problem is solved by providing an isolated RGMa-binding protein which does not inhibit the binding of RGMa to neogenin and neutralizes the neurite outgrowth inhibitory activity of RGMa, preferably an anti-RGMa antibody in which the amino acid sequence of a complementarity-determining region is an amino acid sequence having a specific sequence in the sequence table and SFG.SELECTED DRAWING: Figure 5

The invention relates to the technical field of medicaments. In particular, the present invention provides pharmaceutical combinations / compositions comprising a type 5 phosphodiesterase (PDE5) inhibitor, arginine, and N-acetylcysteine, and uses thereof in the treatment of cardiovascular diseases and erectile dysfunction.

An object of the present invention is to provide a new cognitive function improving agent containing a component that was not previously known to improve cognitive function, and to clarify the mechanism of action of the component's cognitive function improving effect. A further object of the present invention is to provide a new neurite outgrowth agent and to use the neurite outgrowth agent as a composition for treating neurodegenerative diseases. The present invention provides a cognitive function improving agent or a neurite outgrowth agent containing 2-O-trans caffeoylhydroxycitric acid, which preferably contains 2-O-trans caffeoylhydroxycitric acid derived from coriander.

The present disclosure provides a method of treating or ameliorating a disease or disorder comprising administering to a subject a crystalline form of a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. The disclosure further provides a method of stimulating neurogenesis or neurite growth resulting in an increase in neuronal length.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients. In another aspect, tryptamine compositions described herein enhance neuroplasticity by promoting neuronal branching through the formation of neurites (i.e., neurite outgrowth) and neurite elongation (i.e., increasing neurite length).

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

Described herein are neurotrophic and nootropic compositions and methods for treating subjects with such compositions. In one aspect the composition comprises one or more tryptamines or in pure form or extracts from psilocybin containing mushrooms, or combinations thereof optionally combined with one or more phenethylamines or amphetamines in pure form or extracts from a plant or mushroom, or combinations thereof, optionally one or more erinacines or hericenones in pure form, extracts from Hericium mushroom species (e.g., H. erinaceus, H. coralloides, H. ramosum) or combinations thereof, optionally one or more cannabinoids in pure form or extracts from Cannabis sativa, Cannabis sativa, Cannabis indica, or Cannabis ruderalis, optionally, one or more adversive compounds, and optionally one or more pharmaceutically acceptable excipients.

The present disclosure provides a method of treating a mental health and / or central nervous system disorder, or a stress-related disease, which may include administering to a pharmaceutical composition including a therapeutically effective amount of a non-hallucinogenic 5-HT2A receptor agonist or an effective amount of a compound that does not have an agonist activity on 5-HT2A serotonin receptor to a subject in need thereof.

The invention belongs to the technical field of medicines, and particularly relates to nucleic acid gel for mediating spinal cord injury repair by remodeling a residual neural circuit as well as a construction method and application of the nucleic acid gel. The nucleic acid gel disclosed by the invention integrates PTEN targeted inhibition mediated neurite growth and 5-HT mediated neuron excitement recovery, so that the unification of dormant residual neuron reactivation and spinal cord loop reconstruction is realized in spinal cord injury repair. A novel synergetic normal form is provided for spinal cord injury treatment by synergetic structure reconstruction and functional recovery on a drug delivery platform in a single focus.

The application discloses a ketamine derivative and application thereof in treatment of mental diseases, and belongs to the technical field of medicines.The compound or the pharmaceutical composition thereof can obviously improve the expression amount of nerve cell BDNF, promote neurite growth, inhibit NMDA receptor signal and treat acute and chronic anti-depression, and has improved oral bioavailability relative to ketamine, and can be used for treating mental diseases such as depression.